RxDoctor Payments Data

Deborah Kwon

Cardiovascular Disease · Cleveland, OHNPI 1881868834

Payments from drug & device makers

$33,686in general payments, 2019–2025

Across 35 payments — averaging $962.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$26K
  • Pfizer$3K
  • Guerbet LLC$2K
  • GE HealthCare$1K
  • Siemens Medical Solutions USA, Inc.$783
  • Myocardial Solutions, Inc.$650
  • plus $74 from 1 others

What the payments were for

  • Consulting fees$3,62555%
  • Travel & lodging$1,97930%
  • Food & beverage$1,03216%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Philips North America LLC5$26,400
Pfizer2$2,875
Guerbet LLC5$1,805
GE HealthCare11$1,098
Siemens Medical Solutions USA, Inc.10$783
Myocardial Solutions, Inc.1$650
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$74

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,686 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$58,209
Medicare patients
548
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$122,508
EliquisApixaban65$71,498
EntrestoSacubitril/Valsartan67$67,330
Metoprolol Succinate282$4,339
Valsartan62$3,459
Colchicine19$2,504
Rosuvastatin Calcium97$1,607
Dofetilide14$1,188
Atorvastatin Calcium94$1,013
Ezetimibe30$765
Spironolactone64$722
Torsemide31$615
Lisinopril74$503
Carvedilol44$496
Irbesartan12$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,875$71,49865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →